Iron Deficiency Anemia Therapy Market Size

Iron Deficiency Anemia Therapy Market Size

Iron Deficiency Anemia Therapy Market size was valued at around USD 4.3 billion in 2023 and is estimated to grow at 6.5% CAGR from 2024 to 2032. Iron deficiency anemia is a condition characterized by a lack of adequate healthy red blood cells due to insufficient iron levels. Iron is essential for producing hemoglobin, the protein in red blood cells that carries oxygen throughout the body. Iron levels are low, the body cannot produce enough hemoglobin, leading to symptoms such as fatigue, weakness, pale skin, shortness of breath, and dizziness.

The rising prevalence of iron deficiency anemia is a significant driver for the market. For instance, according to the World Health organization, in 2023, it is estimated that globally 40% of children aged 6–59 months, 37% of pregnant women, and 30% of women aged 15–49 years are affected by anemia. This resulted into an urgent need for increased investment in effective treatments and public health interventions to combat iron deficiency anemia. It highlights the growing necessity for developing and implementing effective anemia therapies and strategies.
 

Furthermore, increasing awareness and diagnosis, advancements in treatment options, growing geriatric population, are the promoting factors advancing the growth of the market.